954136-51-7

Upstream product

• 953394-05-3 4-dibenzylamino-2,5-dimethylbenzaldehyde hydrochloride 
• 107-21-1 ethylene glycol 
• 100-39-0 benzyl bromide 
• 117832-13-0 2,5-dimethyl-4-iodoaniline 
• 953394-03-1 dibenzyl-(4-iodo-2,5-dimethylphenyl)amine 
• 953507-02-3 4-dibenzylamino-2,5-dimethylbenzaldehyde 

Downstream Products

• 953394-06-4 C-4-[1,3]Dioxolan-2-yl-2,5-dimethylphenylamine 
• 1253582-37-4 biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-formyl-2,5-dimethyl-phenylcarbamoyl)butyl]methylcarbamoyl}ethyl)piperidin-4-yl ester 
• 1253580-09-4 biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-2,5-dimethylphenylcarbamoyl)butyl]methylcarbamoyl}ethyl)piperidin-4-yl ester 
• 1253582-38-5 biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-{[(R)-2-(tert-butyldimethyl-silanyloxy)-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)-ethylamino]methyl}-2,5-dimethylphenylcarbamoyl)butyl]methylcarbamoyl}ethyl)piperidin-4-yl ester 
• 1253582-62-5 (4-amino-2,5-dimethylphenyl)methanol 

Relevant academic research and scientific papers

DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

This invention relates to a compound of formula I; or a pharmaceutically acceptable salt thereof. Such compounds possess both muscarinic receptor antagonist and β2 adrenergic receptor agonist activities. The invention also relates to pharmaceutical compositions comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compounds as bronchodilating agents to treat pulmonary disorders.

Crystalline forms of a dimethylphenyl compound

The invention relates to crystalline free base forms of biphenyl-2-ylcarbamic acid 1-[2-(4-{[(R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]methyl}-2,5-dimethylphenylcarbamoyl)ethyl]piperidin-4-yl ester or a solvate thereof. This invention also relates to pharmaceutical compositions containing or prepared from such crystalline forms; processes and intermediates useful for preparing such crystalline forms; and methods of using such crystalline forms to, for example, treat a pulmonary disorder.

Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

This invention relates to compounds of formula I: wherein R1 and R2 are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions and combinations comprising such compounds, processes and intermediates for preparing such compounds, and methods of using such compound to, for example, treat pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.